EBS
$41.99
Emergent Biosolutions
$.10
.24%
EBS
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  $3.97
Revenue:  $576.96 Mil
Thursday
Feb 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EBS reports earnings?
Beat
Meet
Miss

Where is EBS's stock price going from here?
Up
Flat
Down
Stock chart of EBS
Analysts
Summary of analysts' recommendations for EBS
Score
Grade
Pivots
Resistance
$44.20
$43.54
$42.77

$42.11

Support
$41.34
$40.68
$39.91
Tweet
Growth
Description
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalMerck & Co.ZoetisEli LillyBristol-Myers SquibbInterCeptPfizer